

© Copyright is owned by the Author of the thesis. The thesis cannot be reproduced or disseminated without the permission of the Author.

**Phytochemical-rich potato extracts and potential for
risk reduction in tamoxifen treatment of breast cancer**

**A thesis presented in partial fulfilment of the requirements for
the degree of**

**Doctor of Philosophy
in
Nutritional Science**

**at Massey University, Palmerston North,
New Zealand.**

**Esther Swee Lan Chong
2013**

MASSEY UNIVERSITY

Application for Approval of Request to Embargo a Thesis
(Pursuant to AC98/168 (Revised 2), Approved by Academic Board 17/02/99)

Name of Candidate: Swee Lan CHONG (Esther) ID Number: 94121795
Degree: Doctor of Philosophy Dept/Institute/School: IFNHH
Thesis title: Phytochemical-rich potato extracts and potential for risk-reduction in tamoxifen treatment of breast cancer.
Name of Chief Supervisor: Prof. Julian Heyes Telephone Ext: 81471

As author of the above named thesis, I request that my thesis be embargoed from public access until (date) 31/7/2015 for the following reasons:

- ☐ Thesis contains commercially sensitive information.
- ☐ Thesis contains information which is personal or private and/or which was given on the basis that it not be disclosed.
- ☒ Immediate disclosure of thesis contents would not allow the author a reasonable opportunity to publish all or part of the thesis.
- ☒ Other (specify): potential opportunity for commercialisation is being explored.

Please explain here why you think this request is justified:

The challenges and time required to publish my work, which is medical or health-related, justify for this embargoing of my thesis. Also, I am actively exploring the potential of commercialisation of the potato extract that came out of this thesis. Thank you.

Signed (Candidate): [Signature] Date: 11/7/13

Endorsed (Chief Supervisor): [Signature] Date: 11/7/13

Approved/Not Approved (Representative of VC): [Signature] Date: 23/7/2013

Note: Copies of this form, once approved by the representative of the Vice-Chancellor, must be bound into every copy of the thesis.

Abstract

Existing data suggest an inverse correlation between breast cancer risk and vegetable consumption, and the anticancer effects of vegetables are attributed to the diversity and abundance of phytochemicals. Standard endocrine therapies for breast cancer are associated with significant side effects and not always effective. Undoubtedly, there is a need for improved treatment of breast cancer. In the quest for better breast cancer treatments with fewer side effects, food and nutrition represent a logical strategy to explore. Potato (*Solanum tuberosum* L.) was chosen for the present project as the target vegetable for investigation. Pigmented potato has recently attracted research attention because of its potential health benefits. Two potato extracts were prepared from a white and purple variety ('Urenika') and referred to as WPE and PPE respectively. Tamoxifen and estradiol exhibited paradoxical effects: each of them was inhibitory at high doses but stimulatory at low to moderate doses, on proliferation of two breast cancer cell lines, MCF-7 and T-47D. In contrast, both PPE and WPE inhibited cell proliferation in a dose-dependent manner without paradoxical effects. The potato extracts also blocked estradiol- or tamoxifen-induced cell proliferation of these two cell lines. These findings imply that both potato extracts may have a role to play in prevention of breast cancer, or complementing tamoxifen to achieve desirable treatment efficacy. Since both PPE and WPE were equivalent in efficacy, one (PPE) was selected for further study, given the intention of developing a nutraceutical or therapeutic product of New Zealand proprietary value. Phytochemical compositions of the potato extracts were identified and quantified using ultra high performance liquid chromatography-mass spectrometry, many of which were reported for the first time in variety 'Urenika'. Several compounds were found at doses which have been reported individually to exert bioactive effects against cancer. It is possible the antiproliferative effects of potato extracts resulted from more than one of these bioactive compounds working together. Dose-dependent apoptotic effects of PPE were observed in T-47D culture, and a combined effect seems to exist between PPE and tamoxifen in modulating the S and G2/M phase. In summary, the key contributions and significance of current thesis are: (1) demonstration

of the “risk” zone for tamoxifen (10^{-8} to 10^{-6} M) and estradiol (10^{-10} to 10^{-8} M) concentrations which may stimulate breast cancer cell growth. Note that these concentrations of tamoxifen or estradiol are physiologically achievable. Furthermore, one key novel finding is regarding the estradiol dependency of tamoxifen action. Specifically, at low to moderate doses (10^{-9} to 10^{-8} M) of tamoxifen, there is a threshold of estradiol ($> 10^{-8}$ M) which allows a significant inhibitory action to occur. The stimulatory action of tamoxifen and complex interaction between tamoxifen and estradiol observed *in vitro* may partially explain the failure of tamoxifen treatment in some patients. Owing to the vast differences between cell culture experiments and the human body, a more systematic *in vivo* investigation of clinical effects of tamoxifen over a range of different doses under various estradiol concentrations is warranted; (2) pioneering data on the efficacy of ‘Urenika’ extract against breast cancer *in vitro*; (3) a metastatic breast cancer animal model which successfully generated metastasis to distant sites (lymph nodes, lungs, livers and spleens), mimicking advanced stage of breast cancer in humans. This model could be used in future testing of the effect of PPE and the combined treatments (PPE with tamoxifen) on establishment and metastasis; and (4) a ‘refined’ non-invasive feeding methodology, which is more ethical than oral gavages, for tamoxifen administration in mice was developed and results obtained were comparable to the method of intraperitoneal injection. Using this model and the non-invasive feeding method, a dose-dependent stimulatory effect of tamoxifen on growth of 4T1 tumours was observed in mice. The current thesis has derived a new hypothesis which may be worth clinical investigation: tamoxifen may induce excessive leukocytosis which contributes to tumour invasiveness and growth. This thesis also represents a significant contribution to the potential use of potato extracts in reducing the risk of tamoxifen in stimulating cancer growth.

Acknowledgements

This thesis marks the end of my perhaps once in a life time PhD journey. My gratitude to all amazing people who have contributed to this project, however, will never end. First and foremost, I wish to convey my utmost gratitude to Dr Fran Wolber, who had amazingly supported my aspiration to do a breast cancer research project. Fran's contributions to my project during those days when she was my principal supervisor are highly appreciated. I wish to acknowledge Professor Marlena Kruger and Associate Professor Jane Coad, for their support and co-supervising the first phase of my project.

I am most grateful to Professor Julian Heyes and Associate Professor Kathryn Stowell for their invaluable contributions to the second phase of my project. In addition, their insightful and valuable feedback during my thesis writing process has helped me greatly. I also wish to thank them for their understanding, encouragement and support during those stressful times of my PhD journey.

I express my warmest thanks to Dr Tony McGhie of Plant & Food Research, who has made my liquid chromatography-mass spectrometry work possible. His expertise, efforts and guidance are greatly appreciated.

I am deeply grateful to Massey University for granting me the doctoral scholarship. I am extremely thankful to Institute of Food, Nutrition and Human Health, which has provided me facilities, resources and a team of great staff. I wish to thank Ms Anne Broomfield for her assistance during the animal trial, and others including Ms Linley Fray, Mr Matthew Levin, Mr Gary Radford, Mr Byron McKillop, Mr Steve Glasgow, Mr Don Thomas and Professor Ravi Ravindran who had helped my work one way or another. I am also thankful to Mr John Edwards, Ms Ann-Marie Jackson and Ms Julia Stevenson of School of Engineering and Advanced Technology for their laboratory support, thoughtfulness and kindness.

Last but not least, I wish to acknowledge my God for constantly renewing my strength, so I could run and not be weary, during this PhD journey, perhaps the most exhausting yet amazing chapter of my life.

*I dedicate this thesis especially to my mother and father,
who work extremely hard for my education,
who encourage me to pursue my dreams,
who catch me when I fall,
whose love sustains me till the end.*

*I also wish to dedicate this thesis to Irene who encourages me throughout
my PhD journey.*

*Lastly, in loving memory, I dedicate this thesis to my late grandmothers and
aunt. My aunt was another breast cancer patient whose bravery in battling
the disease inspired me to contribute to cancer research.*

Table of Contents

Abstract	i
Acknowledgements	iii
Table of Contents	vii
List of Figures	xi
List of Tables	xiv
Abbreviations	xv
Chapter 1	Literature review: current issues with endocrine treatments, and directions for the present thesis 1
1.1	Breast cancer epidemiology: magnitude of the problem 1
1.2	Breast cancer risk factors 3
1.2.1	Reproductive and nutritional factors 3
1.2.2	Alcohol consumption 4
1.2.3	Animal products: dairy, meat and eggs 5
1.2.4	Exposure to biochemical and physical carcinogens 6
1.2.5	Emotional factors: stress & depression 6
1.2.6	Genetic factor 7
1.3	Estrogens: the link between risk factors and breast cancer 8
1.4	Mechanism of estrogen action in breast cancer: Estrogen receptor signaling 9
1.5	Tamoxifen: standard but imperfect treatment 12
1.5.1	Tamoxifen-flare 15
1.6	Other endocrine treatments for ER-positive breast cancer 15
1.6.1	Ovarian ablation 15
1.6.2	Aromatase inhibitor 16
1.6.3	Fulvestrant 17
1.6.4	High-dose estrogen 18
1.7	Treatment for estrogen receptor-negative breast cancer 19
1.8	Treatment for HER2-positive breast cancer: Trastuzumab 19
1.9	The role of plant-based food in breast cancer chemoprevention and treatment 20
1.9.1	Potato: a possible target for research 22
1.9.2	Characterization of plant material for research 25
1.10	Directions and significance of the current thesis 25
1.10.1	To determine dose-response effects of estradiol & tamoxifen on breast cancer cell proliferation in vitro 26

1.10.2	To prepare potato extracts & perform characterisation by ultra high performance liquid chromatography mass spectrometry.....	26
1.10.3	To determine the effects of potato extracts on breast cancer cell proliferation & cell cycle parameters <i>in vitro</i>	27
1.10.4	To establish a metastatic mouse model & test the effects of tamoxifen <i>in vivo</i>	28
Chapter 2	Paradoxical dose-response effects of tamoxifen and estradiol on MCF-7 cell proliferation	29
2.1	Introduction.....	29
2.1.1	Tamoxifen dose-response effects	29
2.1.2	Estradiol dose-response effect	30
2.2	Methods and materials	31
2.2.1	Cell line and cell culture conditions.....	31
2.2.2	Cell proliferation measurements using MTT assay.....	32
2.3	Results	33
2.3.1	Tamoxifen	33
2.3.2	Estradiol & its combined treatments with tamoxifen	34
2.4	Discussion.....	38
2.4.1	Tamoxifen dose-response effects	38
2.4.2	Estradiol dose-response effects	42
2.4.3	Estradiol dependency of tamoxifen action.....	46
2.5	Conclusions	46
Chapter 3	Metabolite profiling and quantification of compounds in potato extracts	48
3.1	Introduction.....	48
3.2	Methods & materials.....	49
3.2.1	Preparation of potato extracts.....	49
3.2.2	Standards.....	51
3.2.3	Ultra high performance liquid chromatography - mass spectrometry : Tentative identification and quantification of compounds present in potato extracts.....	52
3.3	Results	55
3.4	Discussion.....	60
3.4.1	Organic acids.....	60
3.4.2	Amino acids	60
3.4.3	Phenolic acids: hydroxycinnamic acids and its derivatives....	61
3.4.4	Anthocyanins	62
3.4.5	Flavonols.....	64
3.4.6	Hydroxycinnamic acid amides.....	65
3.4.7	Glycoalkaloids.....	65
3.5	Conclusions	66

Chapter 4	Purple and white potato extracts alone inhibit cell proliferation of four breast cancer cell lines (MCF-7, T-47D, MDA-MB-231 and 4T1) and work synergistically with estradiol or tamoxifen.....	67
4.1	Introduction.....	67
4.1.1	Cell proliferation	68
4.1.2	Apoptosis & cell cycle modulation	68
4.2	Methods & materials.....	70
4.2.1	Cell proliferation experiments.....	70
4.2.2	Apoptosis & cell cycle	71
4.2.2.1	Basic principle of flow cytometry.....	71
4.2.2.2	Cell cycle analysis protocol.....	72
4.3	Results	72
4.3.1	Cell proliferation	72
4.3.2	Cell cycle analysis.....	73
4.4	Discussion.....	86
4.4.1	Cell proliferation	86
4.4.1.1	Anthocyanins	88
4.4.1.2	Phenolic acids	92
4.4.1.3	Flavonols	93
4.4.1.4	Glycoalkaloids	94
4.4.2	Apoptosis and cell cycle analysis.....	95
4.4.2.1	Necrosis and apoptosis	95
4.4.2.2	G0/G1 phase	98
4.4.2.3	S & G2/M phase.....	98
4.5	Conclusions	99
Chapter 5	Metastatic mouse breast cancer model 4T1 & tamoxifen dose-response study	101
5.1	Introduction.....	101
5.2	Methods & materials.....	102
5.2.1	Optimization: formulation of tamoxifen solution for intraperitoneal (IP) injection and oral administration	102
5.2.2	Cell line and cell culture conditions	103
5.2.3	Metastatic breast cancer model - animal trial.....	103
5.3	Results	105
5.3.1	Optimization: formulation of tamoxifen solution for intraperitoneal (IP) injection and oral administration	105
5.3.2	Conditioning of jelly-eating behaviour.....	106
5.3.3	Metastatic breast cancer model - animal trial.....	106
5.4	Discussion.....	126
5.5	Conclusions	134

Chapter 6	Overall discussion and future directions.....	135
6.1	Paradoxical effects of tamoxifen on MCF-7 and T-47D cell proliferation; estradiol dependency of tamoxifen action	135
6.1.1	Key findings & future direction.....	135
6.1.2	Individualised therapy: Use of MTT to study preclinical drug sensitivity or resistance.....	137
6.2	PPE/WPE inhibits MCF-7 and T-47D cell proliferation without paradoxical effects and estradiol dependency, and works in synergy with tamoxifen	138
6.3	Directions to study molecular actions of PPE: mechanisms involved in tamoxifen-induced stimulation or resistance	140
6.4	Insights from 4T1 metastatic breast cancer study.....	143
6.4.1	Leukocytosis as a useful marker for metastasis and monitoring disease progression	144
6.4.2	Insights into risks associated with tamoxifen.....	145
6.4.2.1	A possible mechanism of tamoxifen resistance: leukocytosis	145
6.4.2.2	Second cancer associated with tamoxifen: is there an increased risk of acute myeloid leukaemia and spleen cancers?	146
6.4.2.3	Hepatic steatosis associated with tamoxifen treatment	146
6.5	Concluding remarks.....	147
References	148
Appendices	183

List of Figures

Figure 1.1	Breast cancer incidence rate between 1965 and 2005 in many countries.....	3
Figure 1.2	Breast cancer incidence versus obesity prevalence in many countries.....	4
Figure 1.3	Estrogen receptor signalling.	11
Figure 2.1	Conversion of MTT.	32
Figure 2.2	MCF-7 cells were treated with tamoxifen at various doses.	35
Figure 2.3	MCF-7 cells were treated with estradiol at various doses.	36
Figure 2.4	MCF-7 cells were treated with tamoxifen and estradiol at various doses.	37
Figure 3.1	Process of making potato extracts	50
Figure 3.2A	UHPL-MS system.	53
Figure 3.2B	Steps involved in LC-MS analysis.	54
Figure 3.3	Base peak chromatogram (BPC) of purple potato extract obtained by UHPLC-ESI-TOF-MS.....	56
Figure 3.4	BPC of white potato extract obtained by UHPLC-ESI-TOF-MS.....	57
Figure 4.1	The cell cycle.....	69
Figure 4.2	MCF-7 cells were treated with PPE or WPE at various doses.	74
Figure 4.3	T-47D cells were treated with various doses of PPE.....	75
Figure 4.4	MCF-7 cells were treated with or without PPE in the presence of various doses of estradiol.	76
Figure 4.5	T-47D cells were treated with or without PPE in combination with various doses of estradiol.	77
Figure 4.6	T-47D cells were treated with or without estradiol in combination with various doses of PPE.	78
Figure 4.7	T-47D cells were treated with different doses of tamoxifen, in combination with PPE of various doses. ..	79

Figure 4.8	MDA-MB-231 cells were treated with PPE at various doses.	80
Figure 4.9	4T1 cells were treated with PPE at various doses.....	81
Figure 4.10	Necrosis results: Tam vs. PPE vs. PPE+Tam.	82
Figure 4.11	Apoptosis results: Tam vs. PPE vs. PPE+Tam.....	83
Figure 4.12	G0/G1 results: Tam vs. PPE vs. PPE+Tam.....	84
Figure 4.13	S+G2M results: Tam vs. PPE vs. PPE+Tam.....	85
Figure 5.1	Primary tumour growth: diameter results.	108
Figure 5.2	% Body weight change in mice during week 3.....	109
Figure 5.3	Chow intake changes of each mouse during week 3....	110
Figure 5.4	Group mean jelly intake during the trial.	111
Figure 5.5	Health score for each of the mouse at the end of the trial.	112
Figure 5.6	Organ specimens excised at the end of trial.	113
Figure 5.7	Spleen weight vs. various treatments.	114
Figure 5.8	Mediastinal lymph node (MLN) 4T1 metastasis vs. various treatments.	115
Figure 5.9	Spleen 4T1 metastasis vs. various treatments.....	116
Figure 5.10	Liver 4T1 metastasis vs. various treatments.....	117
Figure 5.11	Histological view of 4T1 primary tumours resulted from 4T1 cell transplantation into mice.....	118
Figure 5.12	Histological view of metastasis to mediastinal lymph node.....	119
Figure 5.13	Histological view of metastasis to lungs.....	120
Figure 5.14	Histological view of metastasis to livers.	121
Figure 5.15	Histological view of hepatic steatosis (fatty liver).	122
Figure 5.16	Spleen metastasis and extramedullary hematopoiesis (EMH).....	123
Figure 5.17	4T1 Metastatic tumours attached to spleens.	124

Figure 5.18	Potential role of myeloid precursors cells in 4T1 metastasis.	125
Figure A1	Optimisation of cell number to be plated for MTT assay using MCF-7 cell line.....	183
Figure A2	Base peak chromatogram (BPC) obtained by UHPLC-ESI-TOF-MS for phenolics standards.....	184
Figure A3	BPC obtained by UHPLC-ESI-TOF-MS for phenolics and glycoalkaloid standards.....	185
Figure A4	BPC obtained by UHPLC-ESI-TOF-MS for anthocyanin standards.....	186
Figure A5	BPC for standards: (a) Quinic acid (b) Ascorbic acid... 	187
Figure A6	BPC for standards: (c) Citric acid (d) Tyrosine.	188
Figure A7	BPC for standards: (e) Phenylalanine (f) Tryptophan. 	189
Figure A8	BPC for standards: (g) Spermine (h) Spermidine.	190
Figure A9	Organic acids detected in potato extracts.	193
Figure A10	Amino acids detected in potato extracts.....	193
Figure A11	Structures of some phenolic acids.....	193
Figure A12	Chlorogenic acid isomers detected in potato extracts. 	194
Figure A13	Anthocyanins found in PPE.....	195
Figure A14	Flavonols detected in the potato extracts.....	196
Figure A15	Bis(dihydrocaffeoyl) spermidine isomers & N¹,N⁴,N¹²-tris(dihydrocaffeoyl) spermine.	197
Figure A16	Structures of glycoalkaloids detected in potato extracts.	198
Figure A17	Cell cycle distribution histogram.....	199
Figure A18	Conditioning mice to eating the jelly.....	204
Figure A19	Three-day jelly intake of mice subjected to conditioning procedure.....	205
Figure A20	Lung 4T1 metastasis versus various treatment groups.	206
Figure A21	Hepatic steatosis (fatty liver).....	207

Figure A22	Potential role of myeloid precursor cells in 4T1 metastasis.	208
-------------------	--	------------

List of Tables

Table 1.1	Endocrine therapies for estrogen receptor-positive breast cancer: rationale, efficacy & side effects	14
Table 2.1	Effects of tamoxifen treatment on MCF-7 cell proliferation reported in the literature	41
Table 2.2	Effect of estradiol treatment in MCF-7 cell culture.....	44
Table 3.1	Standards for identification and quantification of unknowns.....	51
Table 3.2	Quantity of each compound detected in the potato extracts using UHPLC-ESI-TOF-MS	58
Table 3.3	Intensity of tryptophan molecular ion obtained with positive and negative ionisation modes – a comparison	61
Table 3.4	Proportion of each chlorogenic acid isomer reported for potato tubers.....	62
Table 3.5	Quantity of each flavonol estimated in potato tubers....	64
Table 4.1	Phytochemical concentration in PPE & WPE compared with effective doses reported in the literature.....	90
Table 5.1	Treatment regimes for tamoxifen dose-response study	105
Table 5.2	Tumour development & visible secondary tumours in mice.	107
Table A1	Characterization of unknown compounds in PPE & WPE with UHPLC-ESI-TOF-MS.	191
Table A2	Tamoxifen (Tam) IP solution formulations tested and observations.....	200
Table A3	Jelly formulations created and observations.	201
Table A4	Experiments to determine if there is colour preference for jelly in mouse feeding trial	203

Abbreviations

AC	Adriamycin + cyclophosphamide
ACY	Anthocyanins
AI	Aromatase inhibitor
AML	Acute myeloid leukaemia
ANOVA	Analysis of variance
AP-1	Activation protein-1
ATCC	American Type Culture Collection
BMI	Body mass index
BPC	Base peak chromatogram
BRCA1	Breast cancer susceptibility gene 1
BRCA2	Breast cancer susceptibility gene 2
CA	Caffeic acid
CChA	Cryptochlorogenic acid
CFBS	Charcoal-treated fetal bovine serum
CFCS	Charcol-treated fetal calf serum
ChA	Chlorogenic acid
CMF	Cyclophosphamide + methotrexate + fluorouracil
CO ₂	Carbon dioxide
CT	Computerized Tomography
DAB	p-dimethylaminoazobenzene
DMEM	Dulbecco's minimal essential medium
DMSO	Dimethyl sulfoxide
DNA	Deoxyribonucleic acid
E2	Estradiol
EBCTCG	Early Breast Cancer Trialists' Collaborative Group
EDTA	Ethylenediaminetetraacetic acid
EGF	Epidermal growth factor
EGFR	Epidermal growth factor receptor
EMH	Extramedullary hematopoiesis
EPIC	European Prospective Investigation Into Cancer and Nutrition Italy Study
ER	Estrogen receptor
ERE	Estrogen responsive element
ER-	Estrogen receptor-negative
ER+	Estrogen receptor-positive
ESI	Electrospray ionization
FAC	Fluorouracil + adriamycin + cyclophosphamide
FAO	Food and Agriculture Organization
FCS	Fetal calf serum
FSC	Forward-angle light scatter
GC	Gas chromatography

H&E	Hematoxylin and eosin
HCA	Hydroxycinnamic acids
HER2	Human epidermal growth factor receptor type 2
IC ₅₀	Concentration of an agent which shows 50% inhibition of the response measured (e.g. cell proliferation)
IGF	Insulin growth factor
IGFR	Insulin growth factor receptor
IMEM	Improved minimum essential medium
IMEM-ZO	Improved minimum essential medium, zinc option
IP	Intraperitoneal injection
LHRH	Luteinizing hormone releasing hormone
<i>m/z</i>	Mass-to-charge ratio
MAPK	Mitogen-activated protein kinase
MEM	Minimum essential medium
MF	Methotrexate + fluorouracil
µg/mL	Microgram per Litre
µM	Micromole per Litre
MISS	Membrane-initiated steroid signalling
MLN	Mediastinal lymph node
MRI	Magnetic resonance imaging
MS	Mass spectrometry
MTT	3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
NASH	Nonalcoholic steatohepatitis
NChA	Neochlorogenic acid
OA	Ovarian ablation
PBS	Phosphate buffered saline
PI	Propidium iodide
PI3K	Phosphoinositide 3-kinase
PPE	Purple potato extract
RNase	Ribonuclease
RPMI	Roswell Park Memorial Institute
SEM	Standard error of mean
SSC	Side-angle light scatter
Tam	Tamoxifen
TD	Diameter
TOF	Time-of-flight
UHPLC	Ultra high performance liquid chromatography
WCRF	World Cancer Research Fund
WPE	White potato extract